Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: VACY AS

Market Cap 1.05B 0 109M 94.58M 86.64M 82.07M 153M 10.24B 155M 1.03B 403M 5.04B 408M 399M 17.49B P/E 2026 *
-4.98x
P/E 2027 * -34.8x
Enterprise Value 566M 0 58.5M 50.94M 46.67M 44.21M 82.29M 5.52B 83.32M 555M 217M 2.72B 220M 215M 9.42B EV / Sales 2026 *
-
EV / Sales 2027 * 2.93x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 2018-12-31
President 49 2016-12-31
Director of Finance/CFO 51 2021-05-02
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 2025-04-22
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 106M
+1.44%-0.23%+63.66%+112.12% 54.44B
+4.60%+5.82%+56.35%+43.04% 45.8B
-1.44%+1.51%-12.94%-19.24% 22.98B
-2.69%-0.95%-3.68%+379.00% 20.76B
+3.22%+2.94%+24.02%-35.05% 16.25B
+0.58%+1.24%+15.53%-38.87% 15.34B
-1.01%-2.97%+27.42%+171.92% 13.05B
+3.07%+5.43%+21.37% - 12.37B
+4.95%+13.49%+121.11%+249.05% 12.47B
Average +1.27%+2.19%+34.76%+107.75% 23.72B
Weighted average by Cap. +1.63%+1.38%+39.51%+97.89%

Financials

2026 *2027 *
Net sales - 162M 0 16.7M 14.54M 13.32M 12.62M 23.5M 1.58B 23.79M 158M 61.9M 775M 62.69M 61.34M 2.69B
Net income -208M -0 -21.47M -18.7M -17.13M -16.23M -30.21M -2.03B -30.58M -204M -79.59M -997M -80.6M -78.87M -3.46B -41.58M -0 -4.29M -3.74M -3.43M -3.25M -6.04M -405M -6.12M -40.72M -15.92M -199M -16.12M -15.77M -691M
Net Debt -485M -0 -50.11M -43.63M -39.97M -37.86M -70.49M -4.73B -71.36M -475M -186M -2.33B -188M -184M -8.07B -578M -0 -59.65M -51.94M -47.59M -45.07M -83.91M -5.63B -84.95M -566M -221M -2.77B -224M -219M -9.6B
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.220NOK
Average target price
5.000NOK
Spread / Average Target
+55.28%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!